Evidence map›Paper›PMID 38724780›Full record

ArticleAdvances in experimental medicine and biology2024

Atopic Dermatitis: Disease Background and Risk Factors.

Becky Li, Zelma Chiesa Fuxench

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Becky LiDepartment of Dermatology, Howard University School of Medicine, Washington, DC, USA.
Zelma Chiesa FuxenchDepartment of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. zelma.chiesafuxench@uphs.upenn.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple risk factors have been associated with the development of atopic dermatitis (AD). Recent advances in understanding the role of genetics in this disease have been made, with discovery of the filaggrin (FLG) gene as the most notable so far. In addition to FLG gene mutations as a risk factor for AD, a positive family history of atopic or allergic disease in either parent has been shown to confer a greater risk of developing AD. Atopic dermatitis usually presents early in life and is thought to represent the initial step in the "atopic march," which is characterized by the development of other atopic diseases later in life such as asthma, allergic rhinitis, and/or rhinoconjunctivitis, food allergies, and hay fever. Other comorbid diseases that have been associated with AD include increase risk of viral and bacterial skin infections, neuropsychiatric diseases such as attention-deficit hyperactivity disorders (ADHD), and autistic spectrum disorder (ASD). Patients with AD have also been found to have worse sleep quality overall compared to patients without AD. In this chapter, we will discuss the risk factors associated with development of atopic dermatitis as well as the most commonly reported comorbidities in patients with this disease.

Indexed as

Dermatitis, AtopicAttention Deficit Disorder with HyperactivityAutism Spectrum DisorderComorbidityFilaggrin ProteinsGenetic Predisposition to DiseaseHumansIntermediate Filament ProteinsMutationRisk FactorsFilaggrin ProteinsFLG protein, humanIntermediate Filament ProteinsComorbidities of atopic dermatitisEnvironmental risk factorsEpidermal differentiation complex (EDC)Filaggrin (FLG) geneGenetic risk factorsLoss-of-function (LOF) mutationsProfilaggrinSkin barrier functionSocioeconomic impactsTransepidermal water loss (TEWL)

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.